(Q48074795)

8 February 2018

editorial

0 references

title

Checkpoint inhibitors and radiation treatment in Hodgkin's lymphoma : New study concepts of the German Hodgkin Study Group (English)

1 reference

8 February 2018

author name string

C Baues

1

1 reference

8 February 2018

R Semrau

2

1 reference

8 February 2018

U S Gaipl

3

1 reference

8 February 2018

P J Bröckelmann

4

1 reference

8 February 2018

J Rosenbrock

5

1 reference

8 February 2018

A Engert

6

1 reference

8 February 2018

S Marnitz

7

1 reference

8 February 2018

publication date

4 October 2016

1 reference

8 February 2018

Strahlentherapie und Onkologie

published in

1 reference

8 February 2018

volume

193

1 reference

8 February 2018

issue

2

1 reference

8 February 2018

page(s)

95-99

1 reference

8 February 2018

https://scigraph.springernature.com/pub.10.1007/s00066-016-1050-4

exact match

0 references

cites work

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00066-016-1050-4

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-016-1050-4

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-016-1050-4

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-016-1050-4

Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-016-1050-4

Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-016-1050-4

The German evidence-based guidelines for Hodgkin's lymphoma. Aspects for radiation oncologists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-016-1050-4

Kill and spread the word: stimulation of antitumor immune responses in the context of radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-016-1050-4

Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-016-1050-4

The abscopal effect associated with a systemic anti-melanoma immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-016-1050-4

Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-016-1050-4

Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-016-1050-4

Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-016-1050-4

Breath-hold technique in conventional APPA or intensity-modulated radiotherapy for Hodgkin's lymphoma: Comparison of ILROG IS-RT and the GHSG IF-RT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-016-1050-4

Quality of life in long-term Hodgkin's disease survivors with chronic fatigue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-016-1050-4

Persisting fatigue in Hodgkin lymphoma survivors: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-016-1050-4

Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-016-1050-4

Analyses of patterns-of-failure and prognostic factors according to radiation fields in early-stage Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-016-1050-4

New quality assurance program integrating "modern radiotherapy" within the German Hodgkin Study Group

21 January 2018

1 reference

12 December 2020

Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial

1 reference

12 December 2020

Die Rolle der Strahlentherapie bei der Induktion von Antitumor-Immunantworten

1 reference

12 December 2020

Quality control of involved field radiotherapy in the HD 13 and HD 14 trials : Report of the radiotherapy panel of the German Hodgkin Study Group (GHSG).

1 reference

12 December 2020

Die stereotaktische Strahlentherapie unterstützt die Immunantwort

1 reference

12 December 2020

10.1007/S00066-016-1050-4

Identifiers

DOI

1 reference

8 February 2018

1 reference

8 February 2018